Jump to content
  • Sign Up
Sign in to follow this  


Recommended Posts

Epsolay, aka, VERED, S5G4T-1 and DER 45 EV, has reached Phase III clinical trial status according to Drug Development Technology. Epsolay is developed and promoted by Sol-Gel Technologies as "an innovative topical encapsulated benzoyl peroxide cream with a 5% concentration for the treatment of papulopustular rosacea."  Epsolay is designed for those who suffer from Phenotype 4

Usually benzoyl peroxide exacerbates rosacea, but Epsolay is a "silica-based microencapsulation delivery system creates a silica barrier between benzoyl peroxide crystals and the skin, and as a result is expected to reduce irritation typically associated with topical application of benzoyl peroxide, thereby making the drug tolerable to rosacea-affected skin." [1]

In a press release, June 18, 2018, Dr. Alon Seri-Levy, Chief Executive Officer of Sol-Gel, states, “Epsolay is aimed to address the need for more effective treatments for inflammatory papules and pustules of rosacea, a chronic condition for which patients often have low adherence to current drugs.”

Sol-Gel Technologies Ltd., Israel 

As more information is released it will be posted in this thread. If you are a member you can use the 'Notify me of replies' button near the bottom of this post and turn it on for any updates. 

End Notes

[1] Sol-Gel > Pipeline > VERED 

Share this post

Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Sign in to follow this  

  • Create New...